A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States. When Sandoz, a Novartis company, acquired FDA approval for Zarxio (filgrastim-sndz) a ...
In September 2014, the FDA published the first edition of the Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations ...
A judge for the US Court of Appeals for the Federal Circuit declined an Amgen motion for a temporary injunction that would have prevented the launch of the first biosimilar in the US—Novartis’s Zarxio ...
On September 3, 2015, Sandoz Inc. (“Sandoz”) announced that it launched the first biosimilar in the United States, Zarxio ® (filgrastim-sndz). Sandoz began marketing Zarxio ® following a Federal ...
A year ago, providers, plans and pharmacy benefit managers thought they were on the brink of a new era of competitive drug prices. The federal approval of the first biosimilar for sale in the U.S. was ...
The first biosimilar medication approved for use in the U.S. made its way to the market on Thursday, ushering in a new era of competition between such drugs and the original high-cost biologic ...
The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications. The Food and Drug Administration has ...
Pharmaceutical prices are dominating public concerns about health care, according to a recent poll by the Kaiser Family Foundation that shows three-quarters of Americans support limiting how much drug ...
The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015 - Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available ...
zarxio The FDA has approved a supplemental Biologics License Application (sBLA) for Zarxio (filgrastim-sndz; Sandoz) to update the Warnings and Precautions section of the drug label. The Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved filgrastim-sndz, making it the first biosimilar product to receive regulatory approval in the ...
The age of biosimilars in the U.S. has finally dawned with the launch of Novartis' Zarxio, a copy of Amgen's Neupogen (filgrastim). And it's arriving with a 15% discount to win scripts over from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results